reported Q3 FY26 standalone revenue up 11% YoY to ₹1,845 Cr and net profit up 13% to ₹303 Cr; consolidated net sales ₹2,393 Cr (-6% QoQ but +31% YoY profit to ₹326 Cr), with new Wardha facility commercial production starting Feb 2026 (₹182 Cr investment). Choice Equity Broking recommends Buy with target ₹1,700 (stoploss ₹1,480), citing strong momentum and technical breakout; shares up 20.2% YoY, mcap ₹39,643 Cr, promoter holding 44.7%. Trading window closed from April 1, 2026, ahead of FY26 results; analyst coverage initiated with Buy TP ₹1,900 on US expansion (12-13 new products in 2 years), Unichem scale-up.

#WatchOutFor#StockInNews

725 likes·50 comments